Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress [Yahoo! Finance]
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
Oruka Therapeutics, Inc. (NASDAQ: ORKA) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $44.00 price target on the stock.
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $41.00 price target on the stock.